EP2796171B1 - Utilisation de l'amisulpride pour le traitement des nausées et vomissements induits par les opiacés - Google Patents

Utilisation de l'amisulpride pour le traitement des nausées et vomissements induits par les opiacés Download PDF

Info

Publication number
EP2796171B1
EP2796171B1 EP14173186.9A EP14173186A EP2796171B1 EP 2796171 B1 EP2796171 B1 EP 2796171B1 EP 14173186 A EP14173186 A EP 14173186A EP 2796171 B1 EP2796171 B1 EP 2796171B1
Authority
EP
European Patent Office
Prior art keywords
amisulpride
use according
vomiting
emesis
retches
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14173186.9A
Other languages
German (de)
English (en)
Other versions
EP2796171A1 (fr
Inventor
Julian Clive Gilbert
Robert William Gristwood
Nicola Cooper
Gabriel Fox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acacia Pharma Ltd
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2796171(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Priority to PL14173186T priority Critical patent/PL2796171T3/pl
Priority to RS20180349A priority patent/RS57032B1/sr
Priority to SI201131446T priority patent/SI2796171T1/en
Publication of EP2796171A1 publication Critical patent/EP2796171A1/fr
Application granted granted Critical
Publication of EP2796171B1 publication Critical patent/EP2796171B1/fr
Priority to HRP20180436TT priority patent/HRP20180436T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to the use of amisulpride in the therapy of nausea, vomiting and retching.
  • Emesis is the act of vomiting and can be described as the forceful expulsion of gastrointestinal contents through the mouth brought about by the descent of the diaphragm and powerful contractions of the abdominal muscles. Emesis is usually, but not always, preceded by nausea. Retching (or dry heaves) involves the same physiological mechanisms as vomiting, but occurs against a closed glottis. Nausea may be defined as a desire to vomit but which is not associated with expulsive muscular movement.
  • Vomiting, nausea, retching or any combination can be caused by a number of factors including anaesthetics, radiation, cancer chemotherapeutic agents, toxic agents, medicines, for example serotonin reuptake inhibitors, analgesics such as morphine, antibiotics, pregnancy and motion.
  • analgesics such as morphine, antibiotics, pregnancy and motion.
  • Conditions which are associated with vertigo, for example Meniere's disease, can also cause the symptoms.
  • Headache caused by for example migraine, increased intracranial pressure or cerebral vascular haemorrhage can also result in the symptoms.
  • maladies associated with the symptoms include cholecystitis, choledocholithiasis, intestinal obstruction, acute gastroenteritis, perforated viscus, dyspepsia resulting from, for example, gastroesophogeal reflux disease, peptic ulcer disease, gastroparesis, gastric or oesophageal neoplasms, infiltrive gastric disorders (e.g. Menetrier's syndrome, Crohn's disease, eosinophilic gastroenteritis, sarcoidosis and amyloidosis), gastric infections, parasites, chronic gastric volvulus, chronic intestinal ischaemia, altered gastric motility disorders and/or food intolerance or Zollinger-Ellson syndrome.
  • no etiology can be determined, as for example in Cyclic Vomiting Syndrome.
  • the symptoms may be defined as acute when they are present for less than a week.
  • the causes of the symptoms of short duration can be separable from etiologies leading to more chronic symptoms.
  • the symptoms may be defined as chronic when they are present for over a week; these can be continuous or intermittent, and last for months or years.
  • chemotherapeutic agents Two areas of particular clinical relevance are nausea and vomiting resulting from surgical procedures (post-operative nausea and vomiting, or PONV) or chemotherapeutic agents and radiation therapy (chemotherapy-induced nausea and vomiting, or CINV).
  • PONV post-operative nausea and vomiting
  • chemotherapeutic agents and radiation therapy chemotherapy-induced nausea and vomiting, or CINV.
  • the symptoms caused by chemotherapeutic agents can be so severe that the patient refuses further treatment.
  • Three types of emesis are associated with the use of chemotherapeutic agents, i.e. acute emesis, delayed emesis and anticipatory emesis.
  • PONV is a significant issue for patients and healthcare providers. It is rated second only to pain as the complication most feared by patients, and contributes significantly to anxiety and patient distress. Vomiting can have an adverse impact on surgical wound sites, especially upper GI tract surgery.
  • Risk factors for PONV include type of surgery, gender (women are more prone than men to PONV), smoking history, prior history of PONV or motion sickness, length of surgery, use of volatile anaesthetics and opioid analgesic usage. Certain operations seem to be particularly associated with PONV, including procedures on the eyes and ears, laparoscopic cholecystectomy and hysterectomy, breast surgery and major abdominal and gynaecological surgery.
  • PONV is typically treated using a dopamine D2 antagonist such as droperidol.
  • This drug was given a black box warning by the FDA in 2001 on the basis of cardiotoxicity, believed to be related to a propensity of the drug to block HERG channels and cause QT prolongation.
  • Amisulpride an atypical antipsychotic D2 antagonist, has beneficial actions in schizophrenic patients. For patients characterised by predominant negative symptoms, oral doses of 50-300 mg/day are recommended. It is reported in the UKPAR (Special Warnings and Precautions for Use) that amisulpride induces a dose dependent prolongation of the QT interval.
  • Amisulpride is marketed as Solian, a solution for intramuscular administration, comprising water, hydrochloric acid, sodium chloride and amisulpride.
  • An ampoule contains amisulpride at 200 mg/4 ml solution.
  • US4294828 discloses amisulpride and related compounds having anti-apomorphine and anti-serotonin activity.
  • Amisulpride is reported to inhibit apomorphine-induced vomiting in the dog, thereby confirming that amisulpride is a functional D2 antagonist. It is suggested that the compounds should be administered at doses of 50-750 mg/day, e.g. 200 mg/day.
  • the present invention relates to the use in man of amisulpride for the therapy (including treatment and prophylaxis or preventative therapy) of nausea, vomiting or retching, which is induced by an opiate.
  • a product comprising amisulpride and an emetogenic agent may be administered as a combined preparation for separate, simultaneous or sequential use in the therapy of a condition as defined herein.
  • Amisulpride has a single chiral centre and 2 enantiomers exist, i.e. (S-)-amisulpride and (R+)-amisulpride. Substantially pure enantiomer or non-racemic mixtures may be used, but it may be preferred to use racemate or (S-)-amisulpride.
  • amisulpride may be administered at dosages which are not associated with adverse cardiovascular events. It is preferably administered by the routes of administration defined in the claims).
  • a typical dosage, e.g. for intravenous administration is from 1 to 48 mg, e.g. up to 40 mg, preferably 1 to 35 mg or, depending on the circumstances, 5 to 35 mg. Human doses of 2.5 to 20 mg may be effective. The drug may be given once, twice or more often each day It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, drug combination and the severity of the particular condition undergoing therapy.
  • the amisulpride may be in the form of a salt, hydrate or solvate.
  • Salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, such as hydrochlorides, hydrobromides, p-toluenesulphonates, phosphates, sulphates, perchlorates, acetates, trifluoroacetates, propionates, citrates, malonates, succinates, lactates, oxalates, tartrates and benzoates.
  • Salts may also be formed with bases.
  • Such salts include salts derived from inorganic or organic bases, for example alkali metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
  • a pharmaceutical composition containing the active ingredient may be in any suitable form, for example aqueous or non-aqueous solutions or suspensions, dispersible powders or granules, transdermal or transmucosal patches, creams, ointments or emulsions.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or non-aqueous (e.g. oleaginous) solution or suspension.
  • the sterile injectable preparation may also be in a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, phosphate buffer solution, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed, including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Suspensions may be formulated according to the known
  • Aqueous suspensions contain the active ingredient in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such a polyoxyethylene with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate.
  • suspending agents for example sodium carboxymethylcellulose, methylcellulose,
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
  • Non-aqueous (i.e. oily) suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • compositions for injection are typically aqueous, and comprise a buffer, e.g. citrate buffer. No other ingredients may be required.
  • the pH of such a composition may be, for example from 4 to 7, e.g. 5.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are known.
  • the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally occurring gums, for example gum acacia or gum tragacanth, naturally occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the active agent may also be administered in the form of suppositories for rectal administration of the drug.
  • suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • transdermal and transmucosal patches for topical delivery, transdermal and transmucosal patches, creams, ointments, jellies, solutions or suspensions may be employed.
  • fast dissolving tablet formulations may be used, as well as a number of the presentations described above.
  • amisulpride may be administered as tablets, capsules or liquids.
  • Amisulpride at an appropriate concentration determined by one of skill, can be formulated with the drug in question, for example morphine, in a dosing system such as an infusion bag or other appropriate dosage form.
  • amisulpride and an emetogenic agent may be administered to a subject in combination, simultaneously or sequentially.
  • amisulpride is given before treatment with, say, morphine.
  • the route of administration may depend on the condition being treated.
  • Examples of conditions that may be treated by the use of amisulpride include anaesthetics, radiation, cancer chemotherapeutic agents, toxic agents, medicines, for example serotonin reuptake inhibitors, analgesics such as morphine, antibiotics, pregnancy, motion, conditions which are associated with vertigo, for example Meniere's disease, headache, caused by for example migraine, increased intracranial pressure or cerebral vascular haemorrhage, cholecystitis, choledocholithiasis, intestinal obstruction, acute gastroenteritis, perforated viscus, dyspepsia resulting from, for example, gastroesophogeal reflux disease, peptic ulcer disease, gastroparesis, gastric or oesophageal neoplasms, infiltrive gastric disorders (e.g.
  • Menetrier's syndrome Crohn's disease, eosinophilic gastroenteritis, sarcoidosis and amyloidosis
  • gastric infections parasites, chronic gastric volvulus, chronic intestinal ischaemia, altered gastric motility disorders and/or food intolerance and Zollinger-Ellson syndrome.
  • the following studies provide evidence on which the invention is based.
  • the preclinical evidence for efficacy against vomiting in PONV and CINV involves studies in ferrets, whilst efficacy against nausea can be demonstrated in patients receiving a general anaesthetic procedure.
  • Amisulpride white powder, was dissolved in dimethylsulfoxide and then diluted in physiological saline.
  • physiological saline was used for s,c, administration (apomorphine experiments) and 8.3% DMSO in physiological saline was used for i.v. administration (morphine, cisplatin).
  • Apomorphine hydrochloride hemihydrates white powder, was dissolved in physiological saline.
  • Morphine hydrochloride white powder, was dissolved in physiological saline.
  • Cisplatinum II diamine dichloride yellow powder, was dispersed in 0.2% hydroxymethylcellulose in physiological saline.
  • ferrets are placed in individual stainless steel cages (40 x 50 x 34 cm) with a grid floor. Then, the animals are challenged with apomorphine (0.25 mg/kg s.c.), morphine (0.4 mg/kg i.p.) or cisplatin (10 mg/kg i.p.) and immediately observed over at least a 2-hour period. Parameters recorded include: number of ferrets showing retches and vomits; latency to first retching; latency to first vomiting; number of retches; vomiting (number of vomits); number of emesis periods and mean duration of emesis periods. Retching is defined as a rhythmic respiratory movement against a closed glottis, while vomiting is defined as a forced expulsion of upper gastrointestinal contents.
  • apomorphine is used as the emetogen
  • amisulpride or vehicle was administered subcutaneously (s.c. 30 minutes before administration of apomorphine). Animals (6 per group) were treated with vehicle or amisulpride at 1, 10, or 100 ⁇ g/kg given sub-cutaneously. The observation period was 2 hours after apomorphine administration.
  • morphine is used as the emetogen
  • the observation period is 2 hours after administration of the morphine.
  • cisplatin is used as the emetogen
  • the observation period is up to 72 hours, which allows effects on early and late phase emesis to be observed.
  • Apomorphine in the vehicle control group induced emesis in the ferrets over the 2 hour observation period (14.8 ⁇ 4.8 retches, 1.0 ⁇ 0.5 vomits, 3.3 ⁇ 0.9 emesis periods). Retches and vomits occurred 319 ⁇ 53 and 621 ⁇ 308 seconds after administration respectively.
  • Amisulpride given at 1 ⁇ g/kg, 30 minutes before apomorphine decreased the emetic effects of apomorphine as compared with the vehicle control group (6.0 ⁇ 2.2 retches, 0 ⁇ 0 vomits and 1.5 ⁇ 0.6 emesis periods). Amisulpride at 10 and 100 ⁇ g/kg totally inhibited the apomorphine emesis. This demonstrates that, as might be expected, amisulpride blocks dopamine D2 receptors.
  • Morphine in the vehicle control group induces emesis in the ferrets over the 2 hour observation period.
  • Amisulpride reduces the emetic effects induced by morphine, in dose-dependent manner, as compared with the vehicle control group.
  • the ED50 for amisulpride against morphine emesis is calculated.
  • morphine in the control group induced the occurrence of retches and vomits in 6 (retches) and 4 (vomits) of 6 animals, the mean ( ⁇ s.e.m.) values were 33.8 ⁇ 4.7 retches, 1.8 ⁇ 0.7 vomits and 7.5 ⁇ 1.5 emesis periods. Retches and vomits occurred after 213 ⁇ 24 and 374 ⁇ 64 seconds respectively.
  • Amisulpride was given at 3, 6 and 12 mg/kg before morphine. Amisulpride at 3 mg/kg produced small decreases in retches to 28.7 ⁇ 7.1 and emesis periods to 5.2 ⁇ 1.4 and abolished the incidence of vomits.
  • Amisulpride given at 6 mg/kg decreased the incidence of all 3 parameters, retches to 17.8 ⁇ 6.8 (approximately a 50% decrease), vomits to 0.5 ⁇ 0.3 (a 72% decrease) and emesis periods to 3.3 ⁇ 1.1 (a 56% decrease).
  • the data from the first 2 dose levels demonstrate a dose related reduction in emesis with amisulpride.
  • Amisulpride given at 12 mg/kg had no effect on retches 31.7 ⁇ 11.2, but still produced a reduction in vomits to 0.8 ⁇ 0.4 and slight reduction in emesis periods to 5.7 ⁇ 1.5.
  • Cisplatin in the vehicle control group induces emesis over the 72 hour period.
  • Amisulpride reduces the emetic effects of cisplatin, in dose-dependent manner, as compared with the vehicle control group, having an effect on both early and late stages.
  • droperidol is a known agent for the treatment of PONV.
  • droperidol was given 5 minutes before cisplatin (using the methods described above) in 3 animals and it was found that, based on the incidence of nausea and vomiting, amisulpride at 0.6 mg/kg (with one animal which had the exaggerated response excluded) and 2 mg/kg is more effective than droperidol at 3 mg/kg.
  • a formulation of the invention was prepared, suitable for intravenous administration. It is a 2.5 mg/ml citrate-buffered solution (nominal pH 5.0) of amisulpride.
  • the composition is given below.
  • Component % w/v Quantity (g) per vial (10 mL fill) Amisulpride 0.25 0.025 Citric acid monohydrate 0.935 0.0935 Trisodium citrate dihydrate 1.632 0.1632 Sodium chloride 0.18 0.018 Hydrochloric acid dilute qs qs Sodium hydroxide qs qs Water for injection To 100 To 10 mL
  • the effects of amisulpride are studied in patients undergoing routine surgery in a randomised, controlled, open-label phase IIa study of efficacy of a single dose as prophylaxis of post-operative nausea and vomiting.
  • the primary endpoint is the incidence of nausea and vomiting in the 24-hour period post-operation.
  • the drug is administered at the time of the operation.
  • the secondary endpoints are the nausea and vomiting rates and severity (measured separately) over 0-2 hours, 2-6 hours and 6-24 hours post-operation.
  • rescue medication and safety/adverse events are recorded.
  • the data demonstrate the effect of amisulpride against the nausea as well as the vomiting and retching associated with PONV.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

  1. Amisulpride à utiliser dans la thérapie de nausées, vomissements et haut-le-coeur induits par un opiacé.
  2. Amisulpride à utiliser selon la revendication 1, où l'opiacé est la morphine.
  3. Amisulpride à utiliser selon l'une quelconque des revendications précédentes, à administrer par injection intraveineuse, intramusculaire ou sous-cutanée.
  4. Amisulpride à utiliser selon l'une quelconque des revendications 1 ou 2, à administrer par administration rectale, intranasale, buccale, orale, transdermique, sous-linguale ou par inhalation.
  5. Amisulpride à utiliser selon l'une quelconque des revendications précédentes, où le sujet de la thérapie est humain.
  6. Amisulpride à utiliser selon l'une quelconque des revendications précédentes, sous forme d'une dose unitaire comprenant moins de 50 mg d'amisulpride.
  7. Amisulpride à utiliser selon la revendication 6, où la dose unitaire comprend 1 à 35 mg d'amisulpride.
  8. Amisulpride à utiliser selon la revendication 7, où la dose unitaire de 1 à 35 mg est donnée une fois ou deux fois par jour à un sujet humain.
  9. Amisulpride à utiliser selon l'une quelconque des revendications précédentes, qui est sous forme d'un sel pharmaceutique acceptable.
  10. Amisulpride à utiliser selon l'une quelconque des revendications précédentes, à utiliser en combinaison avec un autre médicament anti-émétique.
  11. Amisulpride à utiliser selon la revendication 10, où l'autre médicament anti-émétique est un antagoniste de 5HT3.
  12. Amisulpride à utiliser selon la revendication 11, où l'antagoniste de 5HT3 est l'ondansétron.
  13. Amisulpride à utiliser selon l'une quelconque des revendications précédentes, où le sujet de la thérapie présente des symptômes aigus.
EP14173186.9A 2010-03-11 2011-03-10 Utilisation de l'amisulpride pour le traitement des nausées et vomissements induits par les opiacés Active EP2796171B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL14173186T PL2796171T3 (pl) 2010-03-11 2011-03-10 Zastosowania amisulprydu w leczeniu nudności i wymiotów wywołanych przez opiat
RS20180349A RS57032B1 (sr) 2010-03-11 2011-03-10 Upotreba amisulprida za tretiranje opijatom indukovane mučnine i povraćanja
SI201131446T SI2796171T1 (en) 2010-03-11 2011-03-10 Use of amisulprid for the treatment of nausea and vomiting caused by opiates
HRP20180436TT HRP20180436T1 (hr) 2010-03-11 2018-03-14 Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
EP11709793.1A EP2544657B1 (fr) 2010-03-11 2011-03-10 Utilisation de l'amisulpride pour le traitement des nausées et vomissements postopératoires

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP11709793.1A Division EP2544657B1 (fr) 2010-03-11 2011-03-10 Utilisation de l'amisulpride pour le traitement des nausées et vomissements postopératoires

Publications (2)

Publication Number Publication Date
EP2796171A1 EP2796171A1 (fr) 2014-10-29
EP2796171B1 true EP2796171B1 (fr) 2018-01-31

Family

ID=42136792

Family Applications (3)

Application Number Title Priority Date Filing Date
EP11709793.1A Active EP2544657B1 (fr) 2010-03-11 2011-03-10 Utilisation de l'amisulpride pour le traitement des nausées et vomissements postopératoires
EP14173186.9A Active EP2796171B1 (fr) 2010-03-11 2011-03-10 Utilisation de l'amisulpride pour le traitement des nausées et vomissements induits par les opiacés
EP12188047.0A Active EP2567690B1 (fr) 2010-03-11 2011-03-10 Utilisation de l'amisulpride pour le traitement des nausées et vomissements induits par la chimiothérapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11709793.1A Active EP2544657B1 (fr) 2010-03-11 2011-03-10 Utilisation de l'amisulpride pour le traitement des nausées et vomissements postopératoires

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP12188047.0A Active EP2567690B1 (fr) 2010-03-11 2011-03-10 Utilisation de l'amisulpride pour le traitement des nausées et vomissements induits par la chimiothérapie

Country Status (27)

Country Link
US (11) US9084765B2 (fr)
EP (3) EP2544657B1 (fr)
JP (2) JP5886213B2 (fr)
KR (1) KR101738201B1 (fr)
CN (1) CN102892407B (fr)
AU (1) AU2011225898B2 (fr)
BR (1) BR112012022746B1 (fr)
CA (1) CA2792392C (fr)
CY (3) CY1115487T1 (fr)
DK (3) DK2567690T3 (fr)
EA (1) EA030335B1 (fr)
ES (3) ES2496099T3 (fr)
GB (1) GB201004020D0 (fr)
HK (1) HK1179152A1 (fr)
HR (3) HRP20140745T1 (fr)
HU (1) HUE037088T2 (fr)
IL (1) IL221746A (fr)
LT (1) LT2796171T (fr)
MX (3) MX2012010411A (fr)
NO (1) NO2796171T3 (fr)
NZ (1) NZ602279A (fr)
PL (3) PL2796171T3 (fr)
PT (3) PT2796171T (fr)
RS (3) RS57032B1 (fr)
SI (3) SI2796171T1 (fr)
SM (2) SMT201400127B (fr)
WO (1) WO2011110854A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) * 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
US10761020B2 (en) 2015-09-02 2020-09-01 California Institute Of Technology Method and apparatus for the spectroscopic detection of low concentrations of hydrogen sulfide gas
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
WO2020247603A1 (fr) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Formulations à libération modifiée et utilisations associées
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
MX2023000283A (es) 2020-07-06 2023-02-09 Acacia Pharma Ltd Terapia de nausea y vomito post-operatorio.
WO2023179542A1 (fr) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. Dérivés de 5,8-dihydro-1,7-naphtyridine utiles en tant qu'agonistes de glp-1 pour le traitement du diabète
WO2023198140A1 (fr) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
WO2024125602A1 (fr) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Sels et formes solides d'un composé ayant une activité agoniste de glp-1
WO2024138048A1 (fr) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Agonistes de glp-1 hétérocycliques
WO2024131869A1 (fr) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Agonistes hétérocycliques du glp-1
WO2024169952A1 (fr) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
WO2007067714A2 (fr) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Traitement de séquelles de troubles psychiatriques
NZ570039A (en) 2006-01-27 2011-07-29 Eurand Inc Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
EP1988883A1 (fr) * 2006-02-17 2008-11-12 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP3090743A1 (fr) * 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Compositions pharmaceutiques
WO2009126931A2 (fr) * 2008-04-11 2009-10-15 Xvasive, Inc. Thérapie combinatoire pour trouble bipolaire
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US20130022688A1 (en) 2013-01-24
PT2796171T (pt) 2018-04-24
US20200093792A1 (en) 2020-03-26
AU2011225898B2 (en) 2014-07-03
US20180353473A1 (en) 2018-12-13
BR112012022746A2 (pt) 2016-07-05
US8686019B2 (en) 2014-04-01
JP2016028090A (ja) 2016-02-25
US20210228543A1 (en) 2021-07-29
HRP20140744T1 (hr) 2014-09-26
PT2567690E (pt) 2014-09-03
IL221746A (en) 2017-03-30
US20170087128A1 (en) 2017-03-30
RS53467B (en) 2014-12-31
CY1115485T1 (el) 2017-01-04
HRP20140745T1 (hr) 2014-09-26
CA2792392C (fr) 2018-06-19
SI2567690T1 (sl) 2014-12-31
PL2544657T3 (pl) 2014-10-31
WO2011110854A2 (fr) 2011-09-15
JP5886213B2 (ja) 2016-03-16
CA2792392A1 (fr) 2011-09-15
US9545426B2 (en) 2017-01-17
BR112012022746B1 (pt) 2021-09-28
RS57032B1 (sr) 2018-05-31
US20180042896A1 (en) 2018-02-15
CY1115487T1 (el) 2017-01-04
PT2544657E (pt) 2014-09-03
DK2567690T3 (da) 2014-08-11
ES2665418T3 (es) 2018-04-25
SI2796171T1 (en) 2018-05-31
LT2796171T (lt) 2018-05-10
NZ602279A (en) 2014-08-29
HRP20180436T1 (hr) 2018-05-04
US9084765B2 (en) 2015-07-21
EP2567690A1 (fr) 2013-03-13
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (fr) 2011-11-10
US20150335616A1 (en) 2015-11-26
JP6279526B2 (ja) 2018-02-14
ES2496092T3 (es) 2014-09-18
SI2544657T1 (sl) 2014-12-31
KR20130045241A (ko) 2013-05-03
JP2013522181A (ja) 2013-06-13
EP2796171A1 (fr) 2014-10-29
NO2796171T3 (fr) 2018-06-30
CN102892407A (zh) 2013-01-23
US20130022689A1 (en) 2013-01-24
US9119836B2 (en) 2015-09-01
US20230144973A1 (en) 2023-05-11
MX370629B (es) 2019-12-18
DK2796171T3 (en) 2018-05-07
US20220296570A1 (en) 2022-09-22
US10525033B2 (en) 2020-01-07
EA030335B1 (ru) 2018-07-31
SMT201400127B (it) 2015-05-05
CY1120170T1 (el) 2018-12-12
EP2544657B1 (fr) 2014-07-16
EA201290833A1 (ru) 2013-09-30
US9889118B2 (en) 2018-02-13
HUE037088T2 (hu) 2018-08-28
EP2567690B1 (fr) 2014-07-16
MX2019015396A (es) 2020-02-07
DK2544657T3 (da) 2014-08-11
GB201004020D0 (en) 2010-04-21
ES2496099T3 (es) 2014-09-18
AU2011225898A1 (en) 2012-10-04
CN102892407B (zh) 2016-03-23
MX2012010411A (es) 2012-11-30
KR101738201B1 (ko) 2017-05-19
RS53466B (en) 2014-12-31
EP2544657A2 (fr) 2013-01-16
US10085970B2 (en) 2018-10-02
US20140147517A1 (en) 2014-05-29
PL2567690T3 (pl) 2014-11-28
SMT201400126B (it) 2015-05-05
HK1179152A1 (zh) 2013-09-27

Similar Documents

Publication Publication Date Title
US10525033B2 (en) Use of amisulpride as an anti-emetic
WO2008149062A1 (fr) Buspirone pour le traitement des nausées et des vomissements
CN110603036A (zh) 术后恶心和呕吐的补救治疗
AU2014202535B2 (en) The use of amisulpride as an anti-emetic
AU2016216578B2 (en) The use of amisulpride as an anti-emetic
EA042759B1 (ru) Экстренное лечение постоперационной тошноты и рвоты

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140619

AC Divisional application: reference to earlier application

Ref document number: 2544657

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

R17P Request for examination filed (corrected)

Effective date: 20150428

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

111Z Information provided on other rights and legal means of execution

Free format text: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Effective date: 20160308

17Q First examination report despatched

Effective date: 20160428

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602011045487

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61P0001080000

Ipc: A61K0031400000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/08 20060101ALI20170714BHEP

Ipc: A61K 45/06 20060101ALI20170714BHEP

Ipc: A61K 31/40 20060101AFI20170714BHEP

Ipc: A61K 31/4178 20060101ALI20170714BHEP

Ipc: A61K 31/485 20060101ALI20170714BHEP

INTG Intention to grant announced

Effective date: 20170810

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2544657

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 966738

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011045487

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20180436

Country of ref document: HR

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2796171

Country of ref document: PT

Date of ref document: 20180424

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180418

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2665418

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180425

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20180436

Country of ref document: HR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180502

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20180131

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E015305

Country of ref document: EE

Effective date: 20180413

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E037088

Country of ref document: HU

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180400980

Country of ref document: GR

Effective date: 20180829

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011045487

Country of ref document: DE

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 27759

Country of ref document: SK

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20181102

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180436

Country of ref document: HR

Payment date: 20190305

Year of fee payment: 9

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180436

Country of ref document: HR

Payment date: 20200227

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180436

Country of ref document: HR

Payment date: 20210219

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20210301

Year of fee payment: 11

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 966738

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180131

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180436

Country of ref document: HR

Payment date: 20220225

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180436

Country of ref document: HR

Payment date: 20230309

Year of fee payment: 13

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20230511 AND 20230517

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180436

Country of ref document: HR

Payment date: 20240221

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240326

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20240228

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240220

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240327

Year of fee payment: 14

Ref country code: NL

Payment date: 20240326

Year of fee payment: 14

Ref country code: IE

Payment date: 20240327

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240221

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20240223

Year of fee payment: 14

Ref country code: RO

Payment date: 20240223

Year of fee payment: 14

Ref country code: HU

Payment date: 20240222

Year of fee payment: 14

Ref country code: FI

Payment date: 20240325

Year of fee payment: 14

Ref country code: EE

Payment date: 20240221

Year of fee payment: 14

Ref country code: DE

Payment date: 20240327

Year of fee payment: 14

Ref country code: CZ

Payment date: 20240223

Year of fee payment: 14

Ref country code: BG

Payment date: 20240305

Year of fee payment: 14

Ref country code: PT

Payment date: 20240226

Year of fee payment: 14

Ref country code: GB

Payment date: 20240327

Year of fee payment: 14

Ref country code: SK

Payment date: 20240220

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20240221

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240227

Year of fee payment: 14

Ref country code: SE

Payment date: 20240327

Year of fee payment: 14

Ref country code: RS

Payment date: 20240222

Year of fee payment: 14

Ref country code: PL

Payment date: 20240220

Year of fee payment: 14

Ref country code: NO

Payment date: 20240228

Year of fee payment: 14

Ref country code: MT

Payment date: 20240220

Year of fee payment: 14

Ref country code: LV

Payment date: 20240220

Year of fee payment: 14

Ref country code: IT

Payment date: 20240321

Year of fee payment: 14

Ref country code: HR

Payment date: 20240221

Year of fee payment: 14

Ref country code: FR

Payment date: 20240325

Year of fee payment: 14

Ref country code: DK

Payment date: 20240325

Year of fee payment: 14

Ref country code: BE

Payment date: 20240327

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20240422

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240402

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240401

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20240228

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20240315

Year of fee payment: 14